Citigroup Inc. decreased its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) by 20.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 234,296 shares of the company’s stock after selling 59,957 shares during the period. Citigroup Inc.’s holdings in iTeos Therapeutics were worth $4,576,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Hong Kong Ltd acquired a new stake in shares of iTeos Therapeutics during the 1st quarter worth approximately $67,000. Ensign Peak Advisors Inc acquired a new stake in iTeos Therapeutics in the 1st quarter valued at $73,000. Quantbot Technologies LP acquired a new stake in iTeos Therapeutics in the 2nd quarter valued at $69,000. Mutual of America Capital Management LLC grew its stake in iTeos Therapeutics by 43.5% in the 3rd quarter. Mutual of America Capital Management LLC now owns 4,883 shares of the company’s stock valued at $93,000 after acquiring an additional 1,481 shares during the period. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in iTeos Therapeutics in the 3rd quarter valued at $117,000.
iTeos Therapeutics Stock Up 4.2 %
Shares of ITOS opened at $15.30 on Friday. iTeos Therapeutics, Inc. has a 52-week low of $12.52 and a 52-week high of $28.05. The firm’s fifty day moving average is $14.01 and its two-hundred day moving average is $17.57. The stock has a market cap of $547.19 million, a PE ratio of 49.35 and a beta of 1.33.
Analyst Ratings Changes
A number of research firms recently issued reports on ITOS. JPMorgan Chase & Co. dropped their price target on shares of iTeos Therapeutics from $34.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday, March 16th. HC Wainwright reissued a “buy” rating and issued a $54.00 price target on shares of iTeos Therapeutics in a research note on Friday, March 17th. Finally, Wedbush dropped their price target on shares of iTeos Therapeutics from $45.00 to $33.00 and set an “outperform” rating on the stock in a research note on Thursday, March 16th.
iTeos Therapeutics Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating).
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.